Thromboinflammatory response in SARS-CoV-2 sepsis
Aniello Maiese, G Passaro, Alessandra De Matteis, Valentina Fazio, La Russa Raffaele, Marco Di Paolo
Abstract
Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought.
Topics & Concepts
SepsisMedicineIncidence (geometry)PneumoniaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyInflammatory responseCoronavirus disease 2019 (COVID-19)Intensive care medicine2019-20 coronavirus outbreakInflammationVirologyInternal medicineDiseaseInfectious disease (medical specialty)PhysicsOutbreakOpticsCOVID-19 Clinical Research StudiesSepsis Diagnosis and TreatmentVenous Thromboembolism Diagnosis and Management